Health care professionals who prescribe obesity medications should be knowledgeable on their efficacy, indications, contraindications, adverse effects, benefits, and financial costs
What we do know is that many people regain weight quickly after stopping them, which suggests this may become a lifelong medication for many users, Kevin Thompson, the CEO of 9i Capital Group and the host of the 9innings podcast, told Newsweek
PMID: 12486409 Carlo MD Jr, Loeser RF
However, the company faces intensifying competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound), which has demonstrated superior weight loss efficacy, reshaping prescriber preferences in obesity management [2]
Impact of seasons and festivals on the onset of acute pancreatitis in Shanghai, China